“I marvel that society would pay a surgeon a large sum to remove a patient’s leg but nothing to save it.”

George Bernard Shaw

Diabetes is the world’s most prevalent medical condition affecting 6.5% of the adult population. By 2030, the World Health Organization projects that 1 in every 12 adults will have diabetes, swelling the total number of diabetics from 385 million at present, to over half a billion patients. Phoenix is targeting the 25% of diabetics that suffer from moderate-to-severe peripheral neuropathy as the initial treatment population for its product. These high-risk diabetics, who can be readily identified in clinical practice through a variety of simple tests, are seven times more likely to ulcerate than the diabetic population as a whole and collectively account for over 90% of all foot ulcers. Without intervention, during their lifetimes they will incur an average of $17,500 in per capita, medical expenses due to foot ulceration and related complications.

productPhoenix’s medical technologies is developing a device to directly reduce the incidence of foot ulcers among those diabetics at the greatest risk of ulceration provides a clear and persuasive case for its adoption as the standard of care in this population.

Phoenix’s device, which resembles an ordinary orthotic, is backed by $10 million of prior investment in product development and clinical research. Moreover, the therapeutic method-of-action underlying Phoenix’s technology is built upon world-class science. Combining facets of physics and biology, known as stochastic resonance, is that when low-level “noise” is applied to sensory neurons, the sensitivity of the nerves to external stimuli is improved, not degraded. In effect, it is possible to turn up the volume of sensory signals from the extremities, and to do so in a way that is concordant with the nervous system’s normal response to stimuli.

With fourteen, peer-reviewed studies to support its medical claims and rich market opportunities, Phoenix is looking forward to device launch.

Please contact us for more information about this device and other related devices under development.